Corrigendum

In the January 2006 issue, the footnote to Table 1 was published as “aN-terminal pro-brain natriuretic peptide has yet to be approved by the FDA for risk-stratification purposes in acute coronary syndromes”. This should have appeared as “aN-terminal pro-brain natriuretic peptide has been approved by the FDA for risk-stratification purposes in acute coronary syndromes and recently also for risk-stratification purposes in patients with stable coronary artery disease”.

Table 1 The usefulness of inflammatory biomarkers in diagnosis and risk stratification in acute coronary syndromes.
Full size table